Superficial vein thrombosis

Jump to navigation Jump to search

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor-In-Chief: Alberto Castro Molina, M.D.

Synonyms and keywords: Superficial vein thrombosis; superficial thrombophlebitis; thrombophlebitis; Mondor disease; catheter-related superficial thrombosis; great saphenous vein thrombosis; small saphenous vein thrombosis

Overview

Superficial vein thrombosis (SVT) is thrombosis within the superficial venous system, most commonly involving the great or small saphenous veins in the lower extremities and the cephalic or basilic veins in the upper extremities. Community and primary-care data estimate an annual incidence of roughly 64 to 131 per 100,000 person-years.[1][2] Up to one quarter of patients have concomitant deep vein thrombosis (DVT) at diagnosis and are at risk of subsequent venous thromboembolism (VTE).[3]

Synonyms and keywords

Superficial thrombophlebitis; Mondor disease; catheter-associated superficial thrombosis; great saphenous vein thrombosis; small saphenous vein thrombosis.

Historical Perspective

Current understanding integrates Virchow’s triad and recognizes clinical and pathophysiologic overlap with DVT and pulmonary embolism (PE).[4]

Classification

SVT is classified by anatomic location, thrombus length, and proximity to the deep venous system. Trial-derived pragmatic thresholds useful at the bedside include thrombus length ≥5 cm and distance >3 cm from the saphenofemoral junction to define lower immediate risk of deep extension.[5]

Pathophysiology

Stasis, endothelial injury, and hypercoagulability are central mechanisms. In the lower limb, chronic venous disease and varicose veins are frequent contributors; in the upper limb, catheter-related endothelial injury is typical.[4][6]

Epidemiology and Demographics

Incidence ranges from 64 to 131 per 100,000 person-years in population-based and primary-care cohorts.[1][2] Risk is higher in women, likely reflecting greater prevalence of varicose veins and estrogen exposure.[1] Pregnancy and the postpartum period confer additional risk, particularly within 12 weeks after delivery.[7]

Causes

  • Upper limb: peripheral or central venous catheters and infusion-related phlebitis.[6][8]
  • Lower limb: varicose veins and chronic venous disease, inherited or acquired thrombophilia, active cancer, pregnancy and puerperium.[9][10]

Differentiating Superficial Vein Thrombosis from other Diseases

Common mimics include cellulitis, lymphangitis, erythema nodosum, contusions, and DVT. Misclassification with cutaneous polyarteritis nodosa has been reported and can be avoided by careful clinical–imaging correlation.[11]

Risk Factors

Varicose veins, active cancer, prior VTE, pregnancy and postpartum, obesity, recent immobility or surgery, estrogen exposure, thrombophilia, and upper-extremity catheters are associated with SVT and with concomitant DVT or recurrent VTE.[1][3][7][9]

Natural History, Complications and Prognosis

SVT can extend into the deep system and is associated with subsequent VTE. Pooled analyses describe late VTE events after isolated SVT, with risk concentrated in clinical and anatomic high-risk subgroups.[12] SVT may also be associated with subsequent cancer diagnoses in a minority of patients.[10]

Screening

There is no role for population screening. D-dimer is not reliable to exclude isolated SVT given variable sensitivity and limited negative predictive value in this setting.[13][14][15]

Diagnosis

Clinical Presentation

Typical features include focal pain and erythema along a superficial vein with a palpable, tender cord; pruritus or localized swelling may occur. Upper-extremity SVT typically follows the course of venous access.[4]

Physical Examination

Inspection and palpation are used to map the involved segment, document proximal extent, and assess for diffuse edema suggesting deep involvement. Familiarity with lower-extremity venous anatomy improves bedside assessment and interpretation.[16]

Laboratory Findings

There are no specific laboratory biomarkers for SVT. D-dimer should not be used to exclude isolated SVT because of limited diagnostic performance.[14]

Imaging

Duplex ultrasonography confirms diagnosis, measures thrombus length and distance to deep junctions, and excludes concomitant DVT when suspected or when management decisions depend on anatomy.[4][3]

Treatment

Management is guided by thrombus length, proximity to the deep system, and clinical risk profile.

Local measures Warm compresses, limb elevation, and nonsteroidal anti-inflammatory drugs are commonly used for symptom relief. The routine use of elastic compression is not supported by strong evidence; a randomized trial did not demonstrate significant benefit of compression stockings on thrombus length or pain when added to anticoagulation.[17]

Low-intensity anticoagulation

  • Fondaparinux 2.5 mg once daily for 45 days reduces SVT progression, DVT/PE, and recurrence compared with placebo in patients with thrombus ≥5 cm and >3 cm from the saphenofemoral junction.[5]
  • Rivaroxaban 10 mg once daily is a reasonable oral alternative and was non-inferior to fondaparinux for symptomatic events in higher-risk patients in a non-inferiority randomized trial.[18]

Low-molecular-weight heparin Randomized studies with enoxaparin and other low-molecular-weight heparin (LMWH) regimens show modest, often non-significant reductions versus placebo; some trials were underpowered or stopped early because of slow enrollment.[19][20]

Elastic compression In a randomized study, three weeks of compression stockings in addition to enoxaparin did not significantly reduce thrombus length or pain compared with enoxaparin alone.[17]

Surgical or endovenous intervention Saphenofemoral disconnection was not superior to LMWH for preventing recurrence or VTE and was associated with local complications, so routine use is not recommended.[21]

SVT close to the deep system When the thrombus is within 3 cm of a deep venous junction (for example, the saphenofemoral junction), the condition should be managed as DVT with therapeutic-dose anticoagulation, based on trial eligibility criteria and observed risk of extension.[5]

Prevention

Reducing unnecessary catheter exposure and removing catheters at the earliest signs of phlebitis may lower the risk of upper-extremity SVT. In selected high-risk post-procedural contexts, short courses of LMWH or low-dose direct oral anticoagulants can be considered on an individualized basis.[6]

Guidelines

Evidence from randomized trials supports fondaparinux 2.5 mg once daily for 45 days for SVT ≥5 cm and >3 cm from the saphenofemoral junction, with rivaroxaban 10 mg daily as a reasonable alternative when fondaparinux is not feasible.[5][18] Contemporary reviews endorse this approach as the standard evidence-based regimen.[4]

References

  1. ↑ 1.0 1.1 1.2 1.3 Frappé, P (2014). "Annual diagnosis rate of superficial vein thrombosis of the lower limbs: the STEPH community-based study". J Thromb Haemost. 12 (6): 831–838. doi:10.1111/jth.12575.
  2. ↑ 2.0 2.1 Geersing, GJ (2018). "Incidence of superficial venous thrombosis in primary care and risk of subsequent venous thromboembolic sequelae". BMJ Open. 8 (4): e019967. doi:10.1136/bmjopen-2017-019967.
  3. ↑ 3.0 3.1 3.2 Galanaud, JP (2011). "Predictive factors for concurrent deep vein thrombosis and symptomatic venous thromboembolic recurrence in case of superficial venous thrombosis: the OPTIMEV study". Thromb Haemost. 105 (1): 31–39. doi:10.1160/TH10-06-0406.
  4. ↑ 4.0 4.1 4.2 4.3 4.4 Scott, G; Mahdi, AJ; Alikhan, R (2015). "Superficial vein thrombosis: a current approach to management". Br J Haematol. 168 (5): 639–645. doi:10.1111/bjh.13255.
  5. ↑ 5.0 5.1 5.2 5.3 Decousus, H; Prandoni, P; Mismetti, P (2010). "Fondaparinux for the treatment of superficial-vein thrombosis in the legs". N Engl J Med. 363 (13): 1222–1232. doi:10.1056/NEJMoa0912072.
  6. ↑ 6.0 6.1 6.2 Di Nisio, M (2015). "Treatment for superficial infusion thrombophlebitis of the upper extremity". Cochrane Database Syst Rev (11): CD011015. doi:10.1002/14651858.CD011015.pub2.
  7. ↑ 7.0 7.1 Wiegers, HMG (2023). "Incidence and prognosis of superficial venous thrombosis in pregnancy and postpartum: a nationwide cohort". Lancet Haematol. 10 (5): e359–e366. doi:10.1016/S2352-3026(23)00013-3.
  8. ↑ Cominacini, M (2024). "Incidence and clinical progression of asymptomatic PICC-related thrombosis in patients with solid neoplasms: a prospective cohort". Res Pract Thromb Haemost. 8 (3): 102391. doi:10.1016/j.rpth.2024.102391.
  9. ↑ 9.0 9.1 Legnani, C (2014). "Inherited and acquired thrombophilic alterations in patients with superficial vein thrombosis of the lower limbs". Thromb Haemost. 111 (6): 1194–1196. doi:10.1160/TH13-11-0925.
  10. ↑ 10.0 10.1 Hirmerová, J (2022). "Prevalence of cancer in patients with superficial vein thrombosis and its clinical importance". J Vasc Surg Venous Lymphat Disord. 10 (1): 26–32. doi:10.1016/j.jvsv.2021.05.006.
  11. ↑ Chen, KR (2010). "The misdiagnosis of superficial thrombophlebitis as cutaneous polyarteritis nodosa". Am J Dermatopathol. 32 (7): 688–693. doi:10.1097/DAD.0b013e3181d7759d.
  12. ↑ Galanaud, JP (2012). "Superficial vein thrombosis and recurrent venous thromboembolism: a pooled analysis". J Thromb Haemost. 10 (6): 1004–1011. doi:10.1111/j.1538-7836.2012.04704.x.
  13. ↑ Stein, PD (2004). "D-dimer for the exclusion of acute venous thrombosis and pulmonary embolism: a systematic review". Ann Intern Med. 140 (8): 589–602. doi:10.7326/0003-4819-140-8-200404200-00005.
  14. ↑ 14.0 14.1 Aguilar, C (2005). "D-dimer is not useful for the diagnosis of isolated superficial vein thrombosis". Am J Med. 118 (12): 1417. doi:10.1016/j.amjmed.2005.06.044.
  15. ↑ Gillet, JL (2007). "Predictive value of D-dimer assay in superficial thrombophlebitis of the lower limbs". J Mal Vasc. 32 (2): 90–95. doi:10.1016/j.jmv.2007.01.111.
  16. ↑ Meissner, MH (2005). "Lower extremity venous anatomy". Semin Intervent Radiol. 22 (3): 147–156. doi:10.1055/s-2005-921948.
  17. ↑ 17.0 17.1 Boehler, K (2014). "Compression stockings versus none in isolated superficial vein thrombosis". Eur J Vasc Endovasc Surg. 48 (5): 465–471. doi:10.1016/j.ejvs.2014.07.008.
  18. ↑ 18.0 18.1 Beyer-Westendorf, J (2017). "Rivaroxaban versus fondaparinux in superficial-vein thrombosis: the SURPRISE trial". Lancet Haematol. 4 (3): e105–e113. doi:10.1016/S2352-3026(17)30014-5.
  19. ↑ Superficial Thrombophlebitis Treated by Enoxaparin Study Group (2003). "Low-molecular-weight heparin, nonsteroidal anti-inflammatory drugs, or placebo for superficial thrombophlebitis". Arch Intern Med. 163: 1657–1663. doi:10.1001/archinte.163.14.1657.
  20. ↑ Cosmi, B (2012). "Parnaparin for superficial vein thrombosis: the STEFLUX trial". J Thromb Haemost. 10 (6): 1026–1035. doi:10.1111/j.1538-7836.2012.04727.x.
  21. ↑ Lozano, FS (2003). "Low-molecular-weight heparin versus saphenofemoral disconnection for above-knee great saphenous vein thrombophlebitis". Vasc Endovascular Surg. 37 (6): 415–420. doi:10.1177/153857440303700602.


Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Superficial_vein_thrombosis&oldid=1742066"